Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

Overview of attention for article published in Infection and Drug Resistance, March 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 48 Dimensions

Readers on

mendeley: 41 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 48 publications that cite this research output.

48

The most recent citing publications are shown below. View all 48 publications that cite this research output on Dimensions.

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment

Article in BMC Infectious Diseases (January 2024)

The potential of carbon-based nanomaterials in hepatitis C virus treatment: a review of carbon nanotubes, dendrimers and fullerenes

Article in Discover Nano (September 2023)

Efficacy of Sofosbuvir/Daclatasvir in a Single Tablet for Treating Chronic Viral Hepatitis C

Article in Journal of Clinical Pharmacy and Therapeutics (September 2023)